Aug. 13 at 11:00 a.m. ET

America’s Health Future

Health-care challenges in America were substantial even before COVID-19. The lack of cohesive data sharing and a fragmented system often resulted in poor yet expensive care for patients. What has been learned through this unprecedented time is also offering the opportunity to reimagine today’s approach to health care. Washington Post Live will host a program that examines new and innovative ways those in the medical community are exploring to improve how care is provided, from the rapid growth of telehealth, to analytics platforms for data sharing, to new technologies that may vastly improve the way health care is delivered in a post-coronavirus world. Former Centers for Disease Control and Prevention director Tom Frieden, MD, National Institutes of Health executive Josh Denny, MD and 23andMe CEO and Co-Founder Anne Wojcicki will join the Washington Post's Paige Winfield Cunningham for conversations about how COVID-19 and the expansion of mass data during the pandemic could lead to a more integrated health-care delivery system in the future.
In a segment presented by Optum, we will hear about how they have been approaching health-care system fragmentation, including examples of initiatives and programs that reflect their commitment to whole person care and reducing disparities in care.

Former CDC director Tom Frieden, MD: ‘What we want from our health care system is health’

Former CDC director Tom Frieden, MD, says several issues have put the U.S. in a bad position to handle the coronavirus pandemic, including the lack of a national plan, a disorganized health care system and unsafe facilities. ‘When you step back, big picture, what do we want from our health care system? It’s not complicated. It’s not employment, it’s not revenue, it’s not profits, it’s not employee benefits either. What we want from our health care system is health, and yet, we don’t organize with that principle in mind.’
  • Aug 13, 2020

Former CDC director Tom Frieden, MD, say public health should be supported, not sidelined

Former CDC director Tom Frieden, MD, says we’ve seen an ‘unprecedented hostility toward’ and ‘undermining of’ public health in the U.S. and in some parts of the world. But he says countries that were guided by and fully supported public health are doing better. ‘It’s as if the movers and shakers of the world -- the politicians and business titans of industry -- looked over at public health in the middle of the most disruptive public health crisis in a century and said, ‘Nah, we’re not gonna do that.’...We have a way out to get through this. It’s not by sidelining public health, it’s by supporting public health.’
  • Aug 13, 2020

Former CDC director says CDC hasn’t been allowed to do what it does best in dealing with pandemic

Former CDC director Tom Frieden, MD, says there needs to be an investigation into why the CDC failed to correct issues with the COVID-19 test immediately, but he says the agency can’t shoulder all of the blame for the federal government’s failure in managing the virus. He adds that his former agency hasn’t been allowed to do what it does best, which he calls ‘unfortunate and unsafe.’ ‘Blaming the CDC for the U.S. failures is like blaming someone whose been bound and encased in cement for failing to swim.’
  • Aug 13, 2020

All of Us CEO says COVID-19 has ‘laid bare’ the health disparities that have haunted the U.S.

All of Us CEO Joshua Denny, MD, says the coronavirus pandemic ‘has laid bare some of the health disparities and inequalities that have haunted America for some time.’
  • Aug 13, 2020

All of Us CEO says first step to creating precision treatments is understanding the disease

One of the goals of the All of Us research program is to improve personalized medicine. When asked if precision medicine could aid in the treatment of COVID-19, CEO Joshua Denny, MD, says the first step in personalizing treatments is understanding the disease. ‘Having a rich data set like ours...will be one of those important factors to help us understand the impacts of the disease.’
  • Aug 13, 2020

23andMe finds O blood type appears to be protective against coronavirus

23andMe, a personal genomics and biotechnology company, is examining the genetic factors that influence the severity of the virus. So far, its preliminary data has found that O blood type appears to be protective against the virus, and that race and ethnicity still stand out as a significant risk factor for infection.
  • Aug 13, 2020

23andMe CEO Anne Wojcicki says companies should be transparent when it comes to digital data

When asked how companies should handle privacy concerns related to the digital data collected by wearables like FitBit and other cellphone apps, 23andMe CEO Anne Wojcicki said, “People need to have choice and transparency…I think its really important for people to understand and to know what those choices are, what the decisions are that they’ve made and how the information is being used.’
  • Aug 13, 2020
Tom Frieden, MD

President & CEO, Resolve to Save Lives

Dr. Tom Frieden is the president and CEO of Resolve to Save Lives (an initiative of Vital Strategies) and a senior fellow for global health at the Council on Foreign Relations. He is the former director of the U.S. Centers for Disease Control and Prevention from 2009 to 2017, and the former commissioner of the New York City Department of Health Department. Resolve to Save Lives works with countries to prevent 100 million deaths and to make the world safer from epidemics.
Anne Wojcicki

CEO and Co-Founder, 23andMe

Anne co-founded 23andMe in 2006, three years after the first human genome was sequenced. Her goal was audacious: to help people access, understand, and benefit from the human genome and fundamentally change healthcare in the process. Prior to founding 23andMe, Anne spent a decade on Wall Street investing in healthcare and felt frustrated by a system built around monetizing illness instead of incentivizing prevention. She wanted to flip that model on its head and build a business that helps people prevent illness rather than profit from it. Anne focused on empowering people with direct access to genetic information so that they could use their data to make decisions that could lower their risks for disease. Under her leadership, 23andMe now provides the only personal genetic test with FDA authorization to deliver health information directly to consumers. Anne is a pioneer in the direct-to-consumer DNA testing space and her vision and persistence have allowed 23andMe to provide people with unprecedented access to genetic information. Through its research platform, 23andMe has brought personalized medicine directly to millions of consumers.
Josh Denny, MD

CEO, All of Us Research Program, National Institutes of Health

Josh Denny, MD, MS, is the Chief Executive Officer of the National Institutes of Health’s All of Us Research Program. He has been involved in All of Us from its inception, first as a member of the Advisory Committee to the (NIH) Director Precision Medicine Initiative Working Group, which developed the program’s initial scientific blueprint. He led the program’s initial prototyping project and served as the principal investigator for the All of Us Data and Research Center. As a physician scientist, Josh is deeply committed to improving patient care through the advancement of precision medicine. Before joining the NIH, Josh was a Professor of Biomedical Informatics and Medicine, Director of the Center for Precision Medicine, and Vice President for Personalized Medicine at Vanderbilt University Medical Center. In his roles at VUMC, he was both a practicing internist and a researcher. His research interests include use of electronic health records (EHRs) and genomics to better understand disease and drug response. He also led efforts implementing precision medicine to improve patient outcomes. Josh was a leader in the development of phenome‐wide association studies (PheWAS) and phenotype risk scores. He served as PI for Vanderbilt sites in the Electronic Medical Records and Genomics (eMERGE) Network, Pharmacogenomics Research Network (PGRN), and the Implementing Genomics Into Practice (IGNITE) Network. He is an elected member of the National Academy of Medicine, the American Society for Clinical Investigation, and the American College of Medical Informatics.
Paige Winfield Cunningham

The Washington Post

Content from Optum

Healing a Fractured System

The COVID-19 pandemic has upended the U.S. health-care system and exposed existing gaps in health equity and fragmentation across the health care system. Hear from Optum leaders about how they have been approaching health-care system fragmentation–even before the pandemic, including examples of initiatives and programs that reflect our commitment to whole person care and reducing disparities in care. They will discuss how information is used to address the needs of consumers in a changed world. And how this insightful information ensures member access to quality care and medications in a new and urgent era, resulting in a more equitable system.
  • Aug 13, 2020
Omar Baker, MD, FAAP

Executive Vice President, Strategic Initiatives & Innovation, OptumHealth

Omar Baker, MD, FAAP, is the executive vice president, Strategic Initiatives & Innovation for OptumHealth and chief medical officer, Health Services. Providing insight and guidance on a broad range of strategic, operational and financial initiatives. This includes leading the care delivery component of the Optum Enterprise Strategy, accelerating payer contracting for commercial and Medicaid risk, and driving patient experience strategy.
Daniel Frank, MD

Chief Medical Officer, OptumCare

Daniel Frank, MD, was named chief medical officer of OptumCare in 2019, expanding his most recent role as chief clinical officer of the organization’s clinical performance and affordability teams. Leading their clinical functions, he is responsible for partnering with local care delivery systems across the nation to advance clinical initiatives, foster an exceptional provider experience, improve patient outcomes and transform the way they deliver care.
Moderated by Elisa Steele

Board Director & Former Tech CEO

Elisa currently serves as Chair of the Board of Directors of Cornerstone OnDemand (CSOD) and Namely, where she was previously CEO. She also serves on the boards of Splunk (SPLK), Bumble, Procore Technologies and JFrog. Elisa is an advisor to Tile and Prior to CEO at Namely, she served as CEO at Jive, where she was responsible for the company’s vision and end-to-end global marketing and product functions. She previously served as Jive’s Executive Vice President of Marketing and Products. Prior to Jive, Elisa was Corporate Vice President and CMO of consumer apps and services at Microsoft, including brands such as Bing, Internet Explorer, Lync, MSN, [] and Skype, among others. Earlier in her career, she was the CMO at Skype, EVP and CMO at Yahoo! and SVP of Marketing at NetApp. Elisa holds a M.B.A. from San Francisco State University and a Bachelor’s degree in Business Administration from the University of New Hampshire.
About Washington Post Live
Washington Post Live is the newsroom’s live journalism platform. Top-level government and business leaders, emerging voices and newsmakers discuss the most pressing national and global issues of the day.
    Presenting Sponsor
    Helping people live healthier lives and helping the health system work better for everyone.
    Helping people live healthier lives and helping the health system work better for everyone.